Shoulder joint prostheses
This article was originally published in The Gray Sheet
Metal/polymer/metal nonconstrained or semi-constrained porous-coated uncemented prostheses should be reclassified from Class III into Class II, FDA tentatively concludes in a May 28 Federal Register notice requesting comments on the decision. FDA identifies infection, adverse tissue reaction, pain and/or loss of function, and revision as potential risks to health. In affirming that special controls would reasonably assure the safety and effectiveness of the devices, the agency largely agrees with the recommendation put forth by the Orthopedic and Rehabilitation Devices Panel in January 1998 ("The Gray Sheet" Jan. 26, 1998, p. 8). However, FDA disagrees with the panel's recommendation that postmarket surveillance be used to track adverse device outcomes. Comments are due Aug. 26
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.